Crossref
Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development
Cutis · 2024
DOI: 10.12788/cutis.0995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cutis, 2024. Verfasst von Camile Delva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Camile Delva is from the CUNY School of Medicine, New York, New York. Drs. Pearson and Harris are from the Department of Dermatology, UMass Chan Medi…. Hauptthemen laut MEDLINE: Vitiligo, Drug Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
VitiligoDrug DevelopmentHumansDermatologic AgentsMolecular Targeted Therapy
Substanzen
Dermatologic Agents
Autor:innen und Institutionen
- Camile Delva is from the CUNY School of Medicine, New York, New York. Drs. Pearson and Harris are from the Department of Dermatology, UMass Chan Medical School, Worcester.
Zitieren
APA
Delva, C., Pearson, T. F., & Harris, J. E. (2024). Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. https://doi.org/10.12788/cutis.0995
Vancouver
Delva C, Pearson TF, Harris JE. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. 2024. doi:10.12788/cutis.0995
BibTeX
@article{Delva2024,
author = {Delva, Camile and Pearson, Todd F and Harris, John E},
title = {Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development},
journal = {Cutis},
year = {2024},
doi = {10.12788/cutis.0995}
}
EUVIMED